U.S. markets open in 1 hour 20 minutes
  • S&P Futures

    4,405.75
    +11.00 (+0.25%)
     
  • Dow Futures

    34,761.00
    +71.00 (+0.20%)
     
  • Nasdaq Futures

    15,110.50
    +37.00 (+0.25%)
     
  • Russell 2000 Futures

    2,198.50
    +6.80 (+0.31%)
     
  • Crude Oil

    68.03
    -0.12 (-0.18%)
     
  • Gold

    1,816.80
    +2.30 (+0.13%)
     
  • Silver

    25.55
    +0.08 (+0.33%)
     
  • EUR/USD

    1.1857
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.1840
    0.0000 (0.00%)
     
  • Vix

    17.65
    -0.39 (-2.16%)
     
  • GBP/USD

    1.3928
    +0.0043 (+0.31%)
     
  • USD/JPY

    109.4750
    +0.0070 (+0.01%)
     
  • BTC-USD

    38,131.21
    -240.78 (-0.63%)
     
  • CMC Crypto 200

    946.39
    +19.62 (+2.12%)
     
  • FTSE 100

    7,111.27
    -12.59 (-0.18%)
     
  • Nikkei 225

    27,728.12
    +144.04 (+0.52%)
     

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Corcept Therapeutics (NASDAQ:CORT) has had a great run on the share market with its stock up by a significant 12% over the last three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. In this article, we decided to focus on Corcept Therapeutics' ROE.

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

View our latest analysis for Corcept Therapeutics

How Is ROE Calculated?

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Corcept Therapeutics is:

22% = US$109m ÷ US$490m (Based on the trailing twelve months to September 2020).

The 'return' is the income the business earned over the last year. That means that for every $1 worth of shareholders' equity, the company generated $0.22 in profit.

What Is The Relationship Between ROE And Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

Corcept Therapeutics' Earnings Growth And 22% ROE

First thing first, we like that Corcept Therapeutics has an impressive ROE. Additionally, the company's ROE is higher compared to the industry average of 17% which is quite remarkable. As a result, Corcept Therapeutics' exceptional 41% net income growth seen over the past five years, doesn't come as a surprise.

Next, on comparing with the industry net income growth, we found that Corcept Therapeutics' growth is quite high when compared to the industry average growth of 23% in the same period, which is great to see.

past-earnings-growth
past-earnings-growth

Earnings growth is a huge factor in stock valuation. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. Has the market priced in the future outlook for CORT? You can find out in our latest intrinsic value infographic research report.

Is Corcept Therapeutics Using Its Retained Earnings Effectively?

Summary

On the whole, we feel that Corcept Therapeutics' performance has been quite good. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. With that said, the latest industry analyst forecasts reveal that the company's earnings growth is expected to slow down. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.